Related by context. All words. (Click for frequent words.) 71 bone metastasis 67 metastatic disease 66 brain metastases 66 relapsed ovarian cancer 66 metastatic renal cell carcinoma 65 zoledronic acid 65 hypercalcemia 64 fallopian tube carcinoma 64 HER2 positive metastatic breast 64 hormone refractory prostate cancer 63 hypoparathyroidism 63 HER2 positive breast cancer 63 XGEVA 63 vandetanib 63 chemoradiotherapy 63 castration resistant prostate cancer 63 tumor recurrence 63 neuroendocrine tumors 63 Tavocept 63 metastatic RCC 63 metastases 63 chemoradiation 62 denosumab 62 recurrent NSCLC 62 superficial bladder cancer 62 EBRT 62 non squamous NSCLC 62 distant metastases 62 pain palliation 62 cisplatin chemotherapy 62 relapsing multiple sclerosis 62 osteoporotic fractures 62 HRPC 62 skeletal metastases 62 locoregional 62 metastatic bone 61 TNF antagonist 61 neoadjuvant therapy 61 SHPT 61 soft tissue sarcomas 61 malignancies 61 pertuzumab 61 lupus nephritis 61 pancreatic NET 61 mycophenolate mofetil 61 Amrubicin 61 invasive aspergillosis 61 disease progression 61 anti angiogenic therapy 61 indolent NHL 61 basal cell carcinoma BCC 61 resistant ovarian cancer 61 adjuvant radiation 61 secondary hyperparathyroidism 61 satraplatin 61 myelofibrosis 61 TREANDA 61 sorafenib Nexavar 61 OPAXIO 61 mRCC 60 AA amyloidosis 60 gastrointestinal stromal tumors 60 temozolomide 60 metastatic cancer 60 non metastatic osteosarcoma 60 DMARD 60 recurrent prostate cancer 60 platinum refractory 60 dacarbazine 60 Diabetic Macular Edema 60 Vicinium TM 60 Irinotecan 60 preoperative chemotherapy 60 TORISEL 60 liver metastases 60 AA Amyloidosis 60 Tarceva erlotinib 60 cilengitide 60 malignant pleural mesothelioma 60 oral mTOR inhibitor 60 TEMODAL 60 metastatic prostate cancer 60 Hodgkin lymphoma HL 60 docetaxel chemotherapy 60 axitinib 60 acute GvHD 60 nab paclitaxel 60 recurrent glioblastoma multiforme 60 tumor lysis syndrome 60 hyperphosphatemia 60 antiangiogenic therapy 60 epithelial tumors 60 clinically localized prostate 60 paclitaxel carboplatin 60 invasive candidiasis 60 sorafenib tablets 60 postmenopausal osteoporosis 60 leukemia AML 60 Hepatocellular Carcinoma HCC 60 vertebral fractures 60 FOLFOX4 60 vertebral fracture 60 Bezielle 60 T2DM 60 adjuvant therapy 59 metastatic breast cancer 59 cystectomy 59 androgen deprivation 59 neoadjuvant 59 follicular lymphoma 59 terlipressin 59 diabetic neuropathic pain 59 forodesine 59 metastatic hormone refractory 59 docetaxel 59 prostate cancer HRPC 59 ACTEMRA TM 59 opioid induced bowel dysfunction 59 pathologic fractures 59 recurrent ovarian cancer 59 KRAS mutations occur 59 capecitabine 59 sunitinib 59 CINV 59 CTAP# Capsules 59 relapsed CLL 59 Proxinium TM 59 palifosfamide 59 STRIDE PD 59 prostate cancer CRPC 59 SUTENT 59 recurrent GBM 59 Dapagliflozin 59 Toxicities 59 renal cell carcinoma 59 androgen deprivation therapy 59 castrate resistant prostate cancer 59 phase IIb clinical 59 temsirolimus 59 nonmelanoma skin cancers 59 post herpetic neuralgia PHN 59 EFAPROXYN 59 radiotherapy RT 59 pancreatic adenocarcinoma 59 transplantation HCT 59 ELACYT 59 elotuzumab 59 relapsed refractory 59 deferiprone 59 BCG refractory 59 gout flares 59 standard chemotherapy regimen 59 HuLuc# 59 metastatic HRPC 59 metastatic castration resistant 59 PREOS 59 alvimopan 59 AGILECT R 59 Fibrillex TM 59 goserelin 59 tesmilifene 59 carboplatin paclitaxel 59 bevacizumab 59 odanacatib 59 metastatic renal cell 59 Alpharadin 58 trabectedin 58 Vectibix 58 docetaxel Taxotere ® 58 relapsed multiple myeloma 58 endometrial hyperplasia 58 inhibitor RG# 58 Herceptin trastuzumab 58 cardiac toxicity 58 paclitaxel Taxol 58 relapsing remitting multiple sclerosis 58 Fludara 58 YONDELIS 58 CIMZIA ™ 58 oral ridaforolimus 58 CTEPH 58 remission induction 58 solid tumors 58 distant metastasis 58 refractory angina 58 bortezomib 58 zalutumumab 58 metastatic 58 Erlotinib 58 Neulasta ® 58 chronic HCV infection 58 IV NSCLC 58 tanespimycin 58 opioid induced constipation 58 ixabepilone 58 metastatic gastric 58 diarrhea predominant irritable 58 Bortezomib 58 venous thromboembolic events 58 TACE 58 systemic lupus erythematosus SLE 58 Ophena TM 58 metachronous 58 infusional 5-FU/LV 58 HGS# 58 5-FU/LV 58 bevacizumab Avastin 58 luteinizing hormone releasing 58 5FU 58 AEG# 58 Novartis Zometa 58 bevacizumab Avastin ® 58 vidofludimus 58 Natalizumab 58 gastrointestinal stromal tumors GIST 58 glufosfamide 58 cytotoxic chemotherapy 58 Octreolin 58 MGd 58 Vandetanib 58 metastatic GIST 58 locoregional recurrence 58 febrile neutropenia 58 systemic lupus erythematosus 58 mucositis 58 relapsed AML 58 prostate cancer CaP 58 CoFactor 58 HER2 overexpression 58 CIMZIA TM 58 octreotide LAR 58 anti EGFR antibody 58 LHRH antagonists 58 gemcitabine chemotherapy 58 obatoclax 58 gemcitabine Gemzar 58 endometrial carcinoma 58 posaconazole 58 chemoembolization 58 palifermin 58 relapsed MM 58 ozarelix 58 invasive bladder 58 anthracycline taxane 58 osteoporotic 58 bosentan 58 chronic thromboembolic pulmonary 58 taxane chemotherapy 58 NSCLC 58 GvHD 58 biochemical recurrence 58 CYT# potent vascular disrupting 58 GnRH agonists 58 oral FTY# 58 urothelial bladder cancer 58 anticancer therapy 58 myelodysplastic syndrome MDS 58 pazopanib 58 postoperative chemotherapy 58 metastatic colorectal cancer 58 gemcitabine 58 CBLC# 58 papillary renal cell carcinoma 58 biologic therapy 58 TELINTRA 58 Xanafide 58 IV bisphosphonates 57 docetaxel Taxotere R 57 chlorambucil 57 lymphoma CTCL 57 diabetic gastroparesis 57 oral anticoagulant 57 interferon alfa 57 carcinomas 57 TTF Therapy 57 CA4P 57 trastuzumab 57 bisphosphonates 57 external beam radiotherapy 57 panobinostat 57 FTY# 57 CMV disease 57 topotecan 57 vinorelbine 57 Bevacizumab 57 vismodegib 57 Nexavar ® 57 depsipeptide 57 delay bone metastases 57 severe neutropenia 57 pegfilgrastim 57 advanced adenomas 57 LHRH analogues 57 hepatocellular carcinoma HCC 57 bendamustine 57 sorafenib 57 T DM1 57 mitoxantrone 57 relapsed refractory multiple myeloma 57 EGFR inhibitors 57 noninfectious uveitis 57 CIPN 57 proliferative diabetic retinopathy 57 Myelodysplastic syndromes MDS 57 fallopian tube cancers 57 recurrent metastatic 57 dacarbazine DTIC 57 corticosteroid therapy 57 hepatocellular cancer 57 medullary thyroid cancer 57 bone resorption 57 differentiated thyroid 57 Adjuvant chemotherapy 57 alkylating agent 57 Gemcitabine 57 cutaneous T cell 57 mapatumumab 57 adenomatous 57 OAB symptoms 57 HeFH 57 clodronate 57 idiopathic pulmonary fibrosis IPF 57 tafamidis 57 dasatinib 57 teriflunomide 57 tolvaptan 57 metastatic neuroendocrine tumors 57 retinal vein occlusion 57 evaluating tivozanib 57 VAPRISOL 57 chemotherapy induced neutropenia 57 unresectable stage 57 advanced HER2 positive 57 stage IIIB 57 LHRH agonists 57 metastatic lesions 57 heavily pretreated 57 DU #b 57 Carcinoma 57 talactoferrin 57 unresectable 57 refractory NSCLC 57 chemoradiation therapy 57 FOLFIRI 57 FASLODEX 57 chronic lymphocytic leukemia CLL 57 T1DM 57 PSN# [002] 57 FTY# fingolimod 57 dacetuzumab 57 CINTREDEKIN BESUDOTOX 57 recurrent ovarian 57 operable breast cancer 57 unresectable tumors 57 cabazitaxel 57 hepatocellular carcinoma 57 estramustine 57 hematologic malignancies 57 multiple myeloma MM 57 micafungin 57 severe oral mucositis 57 ximelagatran 57 BAY #-# 57 pCR 57 Hydroxyurea 57 radiochemotherapy 57 paclitaxel poliglumex 57 carboplatin 57 TRISENOX 57 idarubicin 57 Denosumab 57 standard chemotherapy regimens 57 Mimpara 57 ThermoDox ® 57 metastatic kidney 57 EVIZON 57 sunitinib malate 57 doxorubicin 57 tumor shrinkage 57 hematologic disorders 57 relapsed GBM 57 cardiotoxicity 57 APPRAISE 57 Cisplatin 57 osteosarcomas 57 AEGR 57 dirucotide 57 metastatic colorectal 57 advanced NSCLC 57 post herpetic neuralgia 57 Rituxan rituximab 57 SNT MC# 57 FOSRENOL ® 57 cisplatin 57 metastatic melanoma 57 Cimzia TM 57 OncoVEX GM CSF 57 biochemical relapse 57 hyperphenylalaninemia HPA due 57 ACZ# 57 APTIVUS r 57 GISTs 57 variceal bleeding 57 acute leukemias 57 ZOLINZA 57 panitumumab Vectibix 57 cinacalcet 57 SCCHN 57 relapsed SCLC 57 gefitinib 57 esophageal candidiasis 57 Azilect ® 57 prostate cancer AIPC 57 HuMax EGFr 57 AP# [003] 57 breast carcinoma 57 tocilizumab 57 paclitaxel Taxol ® 57 decitabine 57 Telintra 57 pediatric malignancies 57 sorafenib Nexavar ® 57 acute coronary syndromes ACS 57 peripheral sensory neuropathy 57 painful diabetic neuropathy 57 refractory metastatic colorectal cancer 57 elesclomol 57 PEGylated interferon beta 1a 57 Nexavar sorafenib 57 PROVENGE 57 peritoneal carcinomatosis 57 Ceflatonin 57 Sanofi Aventis Taxotere 57 neoadjuvant chemotherapy 57 Follicular Lymphoma 57 Metastatic breast cancer 57 ADHF 57 grade glioma 57 cinacalcet HCl 56 thromboembolic events 56 delayed CINV 56 cSSSI 56 symptomatic paroxysmal AF 56 aflibercept 56 thromboembolic 56 sarcomas 56 vertebral compression fractures 56 osteoporotic fracture 56 carcinoid tumors 56 relapsing remitting MS RRMS 56 biliary tract cancer 56 cell lymphoma CTCL 56 gastrointestinal stromal tumor GIST 56 oral deforolimus 56 DMARDs 56 micrometastases 56 metastatic pancreatic 56 relapsing MS 56 picoplatin 56 sodium thiosulfate STS 56 nitazoxanide 56 ThermoDox R 56 metaglidasen 56 Taxotere ® 56 heterozygous FH 56 neurologic progression 56 anti TNF 56 ruboxistaurin 56 kidney urologic 56 selective androgen receptor modulator 56 monotherapy 56 IRESSA 56 nonvertebral fractures 56 evaluable patients 56 metastatic malignant melanoma 56 opioid analgesia 56 Dasatinib 56 urothelial cancer 56 grade gliomas 56 Panitumumab 56 myelodysplastic syndromes MDS 56 intravenous bisphosphonates 56 cerebral vasospasm 56 AQ4N 56 xanthine oxidase inhibitor 56 ARCOXIA 56 tumor progression 56 Zometa 56 thetreatment 56 acute ischemic stroke 56 esophageal carcinoma 56 chronic periodontitis 56 fibrotic disease 56 subtrochanteric 56 bisphosphonate 56 Azedra 56 alvespimycin 56 Orazol 56 anterior uveitis 56 precancerous cervical lesions 56 colorectal adenoma 56 pegylated liposomal doxorubicin 56 intravesical therapy 56 pancreatic carcinoma 56 peginterferon alfa 2a 56 Renal Cell Carcinoma RCC 56 visilizumab 56 custirsen 56 Anthracycline 56 tamsulosin 56 curative resection 56 hormone receptor positive 56 gefitinib Iressa 56 dirucotide MBP# 56 Neoadjuvant 56 macroalbuminuria 56 amrubicin 56 metastatic colorectal carcinoma 56 ibandronate 56 myeloproliferative diseases 56 docetaxel Taxotere 56 Dacogen injection 56 rheumatoid arthritis psoriatic arthritis 56 parathyroidectomy 56 neratinib 56 lexidronam injection 56 VEGF inhibitors 56 Gemzar ® 56 Protelos 56 endometrial cancers 56 concurrent chemoradiation 56 acute myelogenous leukemia AML 56 SJIA 56 heavily pretreated patients 56 Valsartan 56 imatinib 56 tuberous sclerosis TS 56 esophageal cancers 56 TYZEKA 56 eculizumab 56 microalbuminuria 56 diagnosed GBM 56 situ CIS 56 leukemia ALL 56 TNFerade 56 PSADT 56 enzastaurin 56 erlotinib Tarceva ® 56 subcutaneous formulation 56 cervical lesions 56 renal flares 56 antitumor activity 56 advanced hepatocellular carcinoma 56 NMIBC 56 Degarelix 56 Rituximab 56 gemcitabine cisplatin 56 FOLOTYN ® 56 BRAF inhibitor 56 cervical carcinoma 56 metastatic bladder 56 adjuvant radiotherapy 56 Exherin TM 56 doxorubicin HCl liposome injection 56 DAVANAT 56 afatinib 56 recurrent glioblastoma 56 Pertuzumab 56 ankylosing spondylitis AS 56 refractory AML 56 pediatric acute lymphoblastic 56 vorinostat 56 rituximab 56 lapatinib Tykerb 56 parathyroid carcinoma 56 myelodysplastic syndromes 56 OHR/AVR# 56 anticancer agents 56 Myelodysplastic Syndrome MDS 56 FOLFIRI alone 56 pomalidomide 56 Panzem R NCD 56 Acute Myeloid Leukemia AML 56 REVLIMID 56 erlotinib Tarceva 56 interferon ribavirin 56 BRIM2 56 Doxil ® 56 postoperative ileus POI 56 CRVO 56 Pazopanib 56 tumor resection 56 recurrent malignant glioma 56 plus prednisone 56 cobiprostone 56 PD LID 56 alpha interferons 56 arthritis PsA 56 IRX 2 56 erlotinib 56 severe aortic stenosis 56 oral mucositis 56 CHOP chemotherapy 56 ruxolitinib 56 prednisone prednisolone 56 malignant neoplasms 56 Tarceva TM 56 prostate cancer mCRPC 56 cytarabine 56 dose cytarabine 56 Metastatic 56 cirrhosis liver failure 56 Metastatic Colorectal Cancer 56 malignancy 56 adecatumumab 56 trastuzumab DM1 56 placebo controlled clinical 56 relapsed ALL 56 chronic HCV 56 epithelial ovarian 56 postoperative ileus 56 Navelbine 56 bladder cancers 56 deforolimus 56 antibody MAb 56 atherosclerotic disease 56 imatinib Gleevec 56 irinotecan chemotherapy 56 HBeAg negative 56 zanolimumab 56 LEP ETU 56 colorectal liver metastases 56 Fludarabine 56 Targretin 56 antiangiogenic agents 56 chronic ITP 56 chronic HBV infection 56 rFVIIa 56 Myocet 55 metastatic lung cancer 55 MYLOTARG 55 Ph + ALL 55 refractory ovarian cancer 55 Neovascular AMD 55 strontium ranelate 55 alendronate 55 eniluracil 55 NEUVENGE 55 colorectal carcinoma 55 Kepivance 55 Cloretazine 55 adjuvant therapies 55 MALT lymphoma 55 Erythropoietic therapies may 55 R sorafenib tablets 55 HBeAg positive patients 55 constipation OIC 55 nonmetastatic prostate cancer 55 cancer cachexia 55 dasatinib Sprycel ® 55 factor Xa inhibitor 55 atacicept 55 Laquinimod 55 Tamibarotene 55 teduglutide 55 Rheumatoid Arthritis RA 55 JAK inhibitor 55 Ranolazine 55 immunomodulatory therapy 55 HuMax CD4 55 epirubicin 55 Troxatyl 55 diagnosed multiple myeloma 55 NATRECOR ® 55 IMC A# 55 metastatic malignant 55 Xelox 55 5 FU 55 receptor tyrosine kinase inhibitor 55 nephrotoxicity 55 rindopepimut 55 hematological malignancy 55 anti TNF alpha 55 nonalcoholic steatohepatitis NASH 55 Fludara ® 55 advanced carcinoid 55 HGS ETR1 55 multiple myeloma 55 carcinoid 55 endocrine therapy 55 Relapsing Remitting Multiple Sclerosis 55 cardiovascular morbidity 55 androgen suppression 55 Atiprimod 55 Sorafenib 55 Pirfenidone 55 chemotherapeutic agent 55 grade cervical intraepithelial 55 hormone refractory 55 nonsmall cell lung cancer 55 debilitating complication 55 Bisphosphonates 55 LHRH receptor positive 55 familial amyloidotic polyneuropathy FAP 55 antitumor effect 55 acetonide FA 55 hormone receptor negative 55 azacitidine 55 imatinib therapy 55 myelofibrosis MF 55 hematological cancers 55 carfilzomib 55 thromboembolic disease 55 serum phosphate 55 HGS ETR2 55 KRAS mutant tumors 55 phase IIa clinical 55 postherpetic neuralgia PHN 55 histologic subtype 55 ErbB2 positive 55 iniparib BSI 55 atherothrombotic disease 55 Taxotere R 55 Daclizumab 55 paroxysmal AF 55 neoadjuvant treatment 55 cetuximab Erbitux R 55 peritumoral brain edema 55 octreotide implant 55 hepatic metastases 55 juvenile idiopathic arthritis 55 omacetaxine mepesuccinate 55 palliation 55 metastatic cancers 55 Torisel 55 renal tumors 55 Velcade bortezomib 55 opioid induced constipation OIC 55 prognostic variables 55 renal insufficiency 55 Prestara 55 allogeneic HSCT 55 cytoreductive surgery 55 Retreatment 55 cytogenetic responses 55 knee osteoarthritis OA 55 median PFS 55 RG# [001] 55 assessing T DM1 55 chronic GVHD 55 Gefitinib 55 paclitaxel Taxol R 55 cutaneous squamous cell carcinoma 55 imatinib mesylate 55 postmenopausal osteoporotic women 55 PXD# 55 interferon gamma 1b 55 alemtuzumab treated 55 taxane therapy 55 arterial thrombosis 55 TroVax ® 55 plus dexamethasone 55 chemo radiotherapy 55 oral candidiasis 55 VIDAZA 55 comparator arm 55 Pemetrexed 55 etoposide 55 diabetic peripheral neuropathy 55 Bone metastases 55 bisphosphonate therapy 55 mTOR inhibitors 55 baminercept 55 riociguat 55 hypercalcaemia 55 liposomal doxorubicin 55 chemoresistant 55 NYHA Class II 55 angiogenesis inhibitor 55 PREZISTA r 55 refractory CLL 55 free survival PFS 55 CMV infection 55 smoldering multiple myeloma 55 taxanes 55 hematologic adverse 55 Advanced Renal Cell 55 invasive fungal infections 55 Mitoxantrone 55 Glufosfamide 55 Femara letrozole 55 OZURDEX ® 55 corticosteroid dexamethasone 55 ACTEMRA 55 Traficet EN 55 generation purine nucleoside 55 Xgeva 55 metastatic renal 55 RNAi therapeutic targeting 55 gastrointestinal toxicities 55 cisplatin gemcitabine 55 HER2 positive 55 squamous 55 Mucositis 55 homozygous familial hypercholesterolemia 55 postoperative atrial fibrillation 55 HCV infection 55 hereditary antithrombin deficiency 55 FOLFOX 55 Neuradiab 55 BEACOPP 55 lenalidomide dexamethasone 55 Castration Resistant Prostate Cancer 55 colorectal cancer CRC 55 daclizumab 55 HER2 negative 55 sarcoma 55 hormone ablation 55 Cutaneous T 55 antiangiogenic agent 55 calcitonin 55 INCB# [002] 55 bexarotene 55 ZACTIMA 55 abiraterone acetate 55 glucocorticoid therapy 55 bardoxolone methyl 55 Golimumab 55 adult chronic ITP 55 CaP 55 mCRC patients 55 HspE7 55 elagolix 55 sustained virologic response 55 complete cytogenetic response 55 investigational humanized monoclonal antibody 55 alemtuzumab 55 Apaziquone 55 chemotherapeutic agents 55 cytopenias 55 bronchogenic carcinoma 55 diabetic nephropathy 55 radical cystectomy 55 cisplatin vinorelbine 55 microvascular complications 55 MyVax R 55 phosphate binders 55 DPP4 inhibitor 55 Entereg R 55 Oxaliplatin 55 rHuPH# 55 Junovan 55 CD3 monoclonal antibody 55 Vaprisol 55 hormonal therapies 55 FOLFOX6 55 palliative radiotherapy 55 glioblastoma multiforme GBM 55 psoriatic arthritis PsA 55 ancrod 55 Aflibercept 55 underwent resection 55 Marqibo 55 DOXIL ® 55 androgen ablation 55 Advagraf 55 postoperative mortality 55 H. pylori eradication 55 novel VDA molecule 55 TheraSphere 55 Taxotere docetaxel 55 Alemtuzumab 55 contralateral breast 55 atherothrombotic events 55 Malignant Melanoma 55 patients evaluable 55 metastatic castrate resistant 55 myelofibrosis polycythemia vera 55 evaluable 55 candidemia 55 androgen independent 55 Carboplatin 55 eosinophilic asthma 55 nilotinib 55 low dose cytarabine 55 risedronate 55 untreated metastatic melanoma 55 immune thrombocytopenic purpura ITP 55 OMAPRO 55 pulmonary metastases 55 HbF 55 anastrozole 55 refractory gout 55 velafermin 55 pulmonary arterial hypertension PAH 55 refractory multiple myeloma 55 FROVA 55 lupus renal disease 55 chronic angina 55 intravenous cyclophosphamide 55 cetuximab 55 IL# PE#QQR 55 relapsed MCL 55 PAOD 55 antiplatelet agent 55 lung metastases 55 carcinoma HCC 55 desvenlafaxine succinate 55 renal toxicity 55 lactic acidosis 55 recurrent DVT 55 gastrointestinal cancers 55 xenograft models 55 chronic hepatitis B 55 EOquin 55 Phase Ib II 55 HIF PHI 55 Acute myeloid leukemia 55 Gliadel Wafer 55 antiarrhythmic drug 55 PCa 55 severe hypoglycemic 55 liver resection 55 Bondronat 55 gastric adenocarcinoma 55 pimecrolimus 54 PSMA ADC 54 CALGB # [001] 54 histologically confirmed 54 carcinoid cancer 54 mTOR inhibitor 54 Satraplatin 54 Defibrotide 54 Fingolimod 54 dosage regimens 54 AKT inhibitor 54 imetelstat 54 multi kinase inhibitor 54 chemotherapy docetaxel 54 TASKi3 54 atherothrombotic 54 Folfox 54 calcineurin inhibitor 54 hyperoxaluria 54 Perifosine 54 Hodgkin lymphoma NHL 54 HER2 + 54 mg/m2 dose 54 hematologic toxicity 54 thrombotic events 54 overactive bladder OAB 54 pathological fractures 54 oxymorphone ER 54 Capecitabine 54 cytoreduction 54 BrachySil TM 54 myelodysplastic myeloproliferative diseases 54 alfa 2a 54 Mepact 54 pancreatic insufficiency 54 Neutropenia 54 blinatumomab 54 PLX# 54 Raptiva R 54 cutaneous T 54 NATRECOR R 54 pan HDAC inhibitor 54 lomitapide 54 ocrelizumab 54 spinal cord compression 54 Folotyn 54 paclitaxel chemotherapy 54 NP2 Enkephalin 54 bosutinib 54 commercialize deforolimus 54 conformal radiotherapy 54 ISTODAX 54 sunitinib Sutent 54 medically inoperable 54 DOXIL 54 chronic eosinophilic leukemia 54 VaD 54 polyneuropathy HIV DSP 54 including eniluracil ADH 54 Lupus Nephritis 54 HZT 54 peripheral neuropathy CIPN 54 serum urate 54 Zerenex 54 EOquin TM 54 AzaSite Plus 54 DFMO 54 Cimzia ® certolizumab pegol 54 seminoma 54 antithrombotic therapy 54 ACAPODENE 54 iniparib 54 BCR ABL inhibitor 54 post surgical adhesions